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PPARαsarenuclearreceptorshighlyexpressedincoloncells.Theycanbeactivatedbytheﬁbrates(cloﬁbrate,ciproﬁbrateetc.)used
to treat hyperlipidemia. Since PPARα transcriptional activity can be negatively regulated by JNK, the inhibition of JNK activity
could increase the eﬀectiveness of PPARα ligands. We analysed the eﬀects of AS601245 (a JNK inhibitor) and cloﬁbrate alone or
in association, on proliferation, apoptosis, diﬀerentiation and the gene expression proﬁle of CaCo-2 human colon cancer cells.
Proliferation was inhibited in a dose-dependent way by cloﬁbrate and AS601245. Combined treatment synergistically reduced
cell proliferation, cyclin D1 and PCNA expression and induced apoptosis and diﬀerentiation. Reduction of cell proliferation,
accompanied by the modulation of p21 expression was observed in HepG2 cells, also. Gene expression analysis revealed that
some genes were highly modulated by the combined treatment and 28 genes containing PPRE were up-regulated, while cloﬁbrate
alone was ineﬀective. Moreover, STAT3 signalling was strongly reduced by combined treatment. After combined treatment, the
binding of PPARα to PPRE increased and paralleled with the expression of the PPAR coactivator MED1. Results demonstrate that
combined treatment increases the eﬀectiveness of both compounds and suggest a positive interaction between PPARα ligands and
anti-inﬂammatory agents in humans.
1.Introduction
PPARs are ligand-activated transcription factors belonging
to the nuclear receptor superfamily. Three molecular forms
of PPAR have been identiﬁed, namely, PPARα,P P A R β/δ,
and PPARγ, and all involved in many diﬀerent biological
processes [1]. PPARα is the predominant PPAR subtype
highly expressed in liver, heart, proximal tubules of kidney
cortex, skeletal muscle, intestinal mucosa, and in brown
adipose tissues that are metabolically very active [2].
Endogenous ligands with high speciﬁcity for PPARα are
long-chain unsaturated fatty acids and fatty acid derivatives
[3, 4]. Fibrates, which are hypolipidemic drugs used in
the treatment of hyperlipidemia, are among the group of
synthetic ligands, which are the most important agonists of
PPARα.2 PPAR Research
Since PPARα is expressed in the digestive tract and
mainly localized in the intestinal mucosa in the small
intestine and in the colon, it has been proposed that a
physiological role of the receptor may be to sense the total
ﬂux of dietary fatty acids in key tissues [5]. Colon epithelial
cells can be physiologically exposed not only to fatty acids
but also to hypolipidemic drugs such as ﬁbrates, all PPARα
agonists. For this reason, there is particular interest to study
the eﬀect of PPARα ligands in colon cancer cells.
Less is known about the role of PPARα in human tu-
mors. Generally, activation of this PPAR by agonists causes
inhibition of tumor cell growth [6, 7]. In contrast, in liver
murine cell models, Wy-14,643, cloﬁbrate, ciproﬁbrate, and
DEHPwereinducersofc-fos,c-jun,junBegr-1,andNUP475
[8]. Indeed, PPARα has been widely employed in hepatocar-
cinogenesisprotocolsforrodents[9,10].However,inhuman
cell models, PPAR ligands downregulate oncogenes and
upregulateproapoptoticgenesalso[11,12].Inparticular,the
proapoptotic role of PPARα ligands has been outlined by a
recent review [13].
Beside ligand induction, PPARα activity can be regulated
by JNK and p38 mitogen-activated protein kinase (MAPK)
phosphorylation. The p38 MAPK phosphorylates the A/B
domain of PPARα and enhances its ligand-dependent tran-
scriptional activity [14]. On the contrary, the activation of
ERK-MAPK decreases PPARα activity [15]. By inhibiting
Rho A, a component of Rho family proteins, which regulate
the JNK and the p38 MAPK cascades, cerivastatin stimulates
PPARα transcriptional activity by reducing its phosphoryla-
tion [16].
AS601245[1,3-Benzothiazol-2-yl-(2-{[2-(3-pyridinyl)
ethyl]amino}-4-pyrimidinyl) acetonitrile; JNK inhibitor V]
has been selected as a potent and selective JNK inhibitor
with anti-inﬂammatory properties [17]. In the present
work, we intend to assess its eﬀect on cloﬁbrate action in
colon cancer cells. In particular, we examined the eﬀects
of AS601245 and cloﬁbrate, alone or in association, on
apoptosis, diﬀerentiation, and PPRE binding activity of
PPARα in CaCo-2 human colon cancer cells and analysed,
through microarray analysis (Aﬀymetrix GeneChip), the
g e n ee x p r e s s i o np a t t e r ni nc o n t r o la n dd r u g - t r e a t e dc e l l s .
Moreover, since the liver is the major target organ expressing
PPARα, to assess whether combined treatment could
produce some toxic eﬀects in liver cells, we tested, through
MTT analysis, the acute toxicity of the both substances
and the eﬀect of single and combined treatments on cell
proliferation and proliferation-related gene expressions in
HepG2 human hepatic cells.
2.MaterialsandMethods
2.1. Cell Culture and Treatments. CaCo-2 and HepG2 cells,
obtained from European Collection of Cell Cultures
(ECACC), were cultured at 37◦C in a humidiﬁed atmosphere
of 5% CO2-air. For all experiments, cells, from 1 to 10
passages, were used. Cells were grown in D-MEM medium
supplementedwith10%fetalbovineserum(HyClone,Italy),
2mM glutamine, 1% nonessential amino acids solution
and 1% antibiotic mixture (penicillin streptomycin) (Sigma,
Milano, Italy).
Treatments with cloﬁbrate and AS601245[1,3-benzothi-
azol-2-yl-(2-{[2-(3-pyridinyl)ethyl]amino}-4-pyrimidinyl)
acetonitrile; JNK inhibitor V] (SPRI, Geneva, Switzerland)
were performed by suspending the drugs in DMSO. The
concentration of vehicle in culture did not exceed 1%.
Moreover, cultures, treated with 1% DMSO alone, were
performed to exclude the vehicle’s eﬀects.
2.2. Cell Proliferation and Viability. CaCo-2 cell proliferation
was evaluated by using the kit “CellTiter-Glo Luminescent
Cell Viability Assay” (Promega, Milano, Italy). This highly
sensitive assay detects the luminescence released by the
metabolically active cells. Quantiﬁcation of luminescence
was expressed as RLU (relative light unit). For the prolif-
eration experiments, treatments were performed by adding
the drugs (at diﬀerent concentrations) to the CaCo-2 cells
seeded at about 4,000 cells/well in a 96-well plate. HepG2 cell
proliferationwasanalysedthroughtheMTTmethod.Brieﬂy,
1500cells/wellwereseededin200μLofserum-supplemented
media and the following day treated with the drugs. 20μL
of 5mg/mL thiazolyl blue tetrazolium bromide (M2128-
SIGMA Aldrich) was subsequently added to the cells and
removed 2 hours later. 100μL of DMSO was added to the
cells, and the absorbance was recorded at 570nm through a
96 well plate ELISA reader. Viability was evaluated through
Trypan blue (T8154 SIGMA Aldrich) exclusion test.
2.3. Detection of Apoptosis. Apoptosis was evaluated, 24 and
48 hours after the treatments, by using a Kit Caspase-GLO
3/7Assay(Promega,Milano,Italy)andconﬁrmedbyTUNEL
test. The Caspase-GLO 3/7 assay determines the amount
of caspase 3 and 7 cleavage of the luminogenic substrate
resulting in luciferase reaction and production of light. The
TUNEL method from Promega (Milano, Italy) consists of
the terminal deoxynucleotidyl transferase-mediated nick-
endlabellingofFITC-conjugateddeoxyuridinetriphosphate.
Incorporated ﬂuorescein was detected using a ﬂuorescence
microscope (Leitz, Dialux 20, Oberkochen, Germany). The
number of apoptotic cells was determined by counting
the percentage of green ﬂuorescence-positive cells. At least,
100 cells were counted for each experiment. CaCo-2 cells
t r e a t e dw i t h1 0m Mb u t y r a t ew e r eu s e da sp o s i t i v ec o n t r o l
of apoptosis.
2.4. Detection of Diﬀerentiated Cells. Diﬀerentiation was de-
termined by counting the dome formation in the control
or treated cells. Dome formation, which can be attributed
to ion and water transport across polarized epithelial cells
[18], was quantiﬁed in conﬂuent CaCo-2 monolayers using
inverted light microscopy and expressed as the number of
domes per square centimetre. Domes were recognised as a
cohesive group of approximately 30 cells or more that were
in a diﬀerent plane of view compared to cells attached to the
culture plate.
Preliminary experiments demonstrated that results ob-
tained by dome count were similar to those obtainedPPAR Research 3
with two other methods (transepithelial electrical resis-
tance (TEER) determination and phosphates alkaline assay)
(data not shown). CaCo-2 cells treated with 2mM sodium
butyrate (Sigma, Milano, Italy) were used as a positive
control.
2.5. RNA Extraction and Array Hybridization. Total RNA
from 3 biological replicates of each treatment was isolated
using TRIzol reagent (Invitrogen, Milano, Italy). Samples
were treated with DNase in order to avoid any genomic
contamination. The quality of the resulting RNA was
determined by using the Agilent 2100 Bioanalyzer (Agilent
Technologies), and RNA content was normalized by using
theThermoScientiﬁcNanoDropND-1000spectrophotome-
ter. RNA samples of each replicate were analyzed by using
Aﬀymetrix GeneChip Human Genome U133A plus 2.0 chips
(Aﬀymetrix).
GCOS software version 1.2 (Aﬀymetrix) was used to
deﬁne the probe cell and to calculate the intensity for each
cell. CEL ﬁles generated were analyzed for the overall data
quality using R/Bioconductor. Then, they were processed
into the Rosetta Resolver dataset for data normalization,
generation of expression values, and statistical analysis.
Expression values of all treatment groups were obtained as
a ratio versus the negative control (1% DMSO).
Diﬀerential analyses between pairs of groups were per-
formed with 1-way ANOVA followed by the Benjamini-
Hochberg multiple testing correction (False Discovery Rate-
FDR cut-oﬀ of 1%) and a Student-Newman-Keuls post
hoc analysis. Finally, diﬀerentially expressed genes were
analysed in Ingenuity Pathway Analysis software version 7.5
(Ingenuity Systems, http://www.ingenuity.com/).
2.6. Real-Time RT-PCR. We selected 4 genes that had
shown an approximately 2-fold change in expression for
further study by RT-PCR in a separate experiment. Two of
these (GANAB and IL6ST) were found to be increased in
Aﬀymetrix analysis, whereas the other two were found to
be decreased (FGFR2 and CCNG). Total RNA was reverse
transcribed into cDNA in a 20μL reaction using the
TaqMan High Capacity cDNA Reverse Transcription Kit
provided by Applied Biosystems. 500ng of total RNA
was used as the starting material from each sample. For
each Real-Time PCR reaction, the reverse transcribed sam-
ple was used as a template. Target mRNA was quan-
tiﬁed using an ABI 7900 HT Fast real-time PCR sys-
tem (Applied Biosystems). Primers were purchased from
Applied Biosystems: GANAB (glucosidase, alpha; neutral
AB, Hs00929274 m1), IL6ST (interleukin 6 signal trans-
ducer (gp130, oncostatin M receptor, Hs00174360 m1),
CCNG (cyclin G2, Hs00171119 m1), and FGFR2 (ﬁbroblast
growth factor receptor 2, Hs01552926 m1). The TaqMan
probes were labelled with a 5  reporter dye (FAM, 6-
carboxyﬂuorescein) and a 3  quencher dye (TAMRA, 6-car-
boxytetramethylrhodamine). Real-time PCR reactions were
carried out in triplicate. Data were analyzed by the ABI
Sequence Detection System (SDS) software using the relative
quantiﬁcation. The fold changes are determined by the
ΔΔCt method as described in Applied Biosystems User
Bulletin no. 2.
2.7. DNA-Binding Activity of PPARα. The PPARα binding
activity assay was performed by using Trans-AM ELISA-
based kit from Active Motif (Carlsbad, CA, USA) according
to the manufacturer’s protocol. Brieﬂy, cell extracts were
incubated in a 96-well plate coated with an oligonucleotide
containing the PPRE motif (5 -AACTAGGTCAAAGGTCA-
3 ). PPAR contained in nuclear extract, speciﬁcally bound
to the immobilized oligonucleotide, was detected by using
an antibody anti-PPARα (clone H-98, from Santa Cruz
Biotechnology) followed by a secondary HRP- (horseradish-
peroxidase-) conjugated antibody (Bio-Rad Laboratories) in
an ELISA-like assay.
2.8. Western Blot Analysis. Total extracts were prepared by
lysis in a buﬀer containing Tris-HCl buﬀer, pH 7.4, 150mM
N a C l ,5 m ME D T A ,1 %N o n i d e tP - 4 0 ,1 m Ms o d i u m
orthovanadate, 1mM phenylmethylsulfonyl ﬂuoride, and
0.05% aprotinin. Insoluble proteins were discarded by high-
speed centrifugation at 4◦C. Protein concentration in the
supernatant was measured in triplicate using a commercially
available assay (Bio-Rad Laboratories, Segrate, Italy).
All proteins were separated by SDS-polyacrylamide
gel and electroblotted on nitrocellulose membrane (Bio-
Rad Laboratories, Segrate, Italy). Membranes were blocked
overnight at 4◦Ci nT r i sb u ﬀered saline (TBS) containing
5% milk plus 0.5% Tween 20 and then incubated at room
temperature with primary antibodies (anti-P-PPAR alpha
(Ser21) from Thermo Scientiﬁc; anti-PPAR alpha from
Millipore; anti-STAT3 clone F-2, anti-p-STAT3 (Tyr705)
clone B-7, anti-PCNA clone FL-261, anticyclin D1 clone
A12 from Santa Cruz Biotechnology; anti-p-STAT3 (Ser727)
from ThermoScientiﬁc; anti-PPARBP (MED1) clone 2A2;
anti-β-actin clone AC-1 from Sigma-Aldrich; anti-P-Jun
from cell signaling; anti-p21 from Abcam and horseradish-
peroxidase-conjugated secondary antibodies (Bio-Rad Lab-
oratories, Segrate, Italy). Detection was carried out by
enhanced chemiluminescence (ECL) according to the man-
ufacturer’s protocol (Amersham-Pharmacia Biotech, Italy,
Cologno Monzese, Italy).
Densitometric analysis was performed by using a soft-
ware program (Multi-Analyst, version 1.1, Bio-Rad Labora-
tories, Segrate, Italy). All results were standardized using the
signal obtained with β-actin.
2.9. Statistical Analysis. The 2-way ANOVA was performed
in the proliferation, apoptosis, diﬀerentiation, and PPRE
binding assays.
3. Results
3.1. Growth of Cloﬁbrate and AS601245-Treated Cells. Both
cloﬁbrate and AS601245 were able to inhibit CaCo-2 cell
proliferation in a dose-dependent way (Figures 1(a) and
1(b)). To evaluate the eﬃcacy on cell growth of the com-
bination of cloﬁbrate and AS601245, we chose doses able4 PPAR Research
to reduce cell proliferation by 20% (IC20) after 48 hours
of treatment. These doses were 5μM cloﬁbrate (IC 20:5 ±
0.4) and 0.1μM AS601245 (IC 20:0.1 ± 0.01). Combined
treatment signiﬁcantly reduced cell growth after 72 and 96
hours from the treatment (Figure 1(c)). The treatment with
two compounds synergistically reduced the cell growth after
72 hours, whereas, after 96 hours, the reduction is less
pronounced.Thedosesof5μMcloﬁbrat e,0.1μMAS601245,
and the combined treatment with these doses were used for
all the subsequent experiments.
3.2. Proliferation-Related Genes Expressions. Since the reduc-
tion of proliferation can be accompanied by the modu-
lation of speciﬁc genes, we determined the expression of
proliferating cell nuclear antigen (PCNA), cyclin D1 and
p21, in CaCo-2 cells. Moreover, we found that AS601245
at the concentration of 0.1μM was able to inhibit Jun
phosphorylation in CaCo-2 cells. In Figure 2(a), the analysis
of P-Jun expression revealed that the amount of P-Jun
protein was reduced in cells treated with 0.1μM AS601245.
A similar result was observed in cells treated with AS601245
plus cloﬁbrate.
The PCNA expression was reduced in CaCo-2 cells only
after72hoursfromthetreatmentswithcloﬁbrate,AS601245,
and their combination (Figure 2(b)). Cyclin D1 expression
was induced by cloﬁbrate 48 hours from the treatment, but,
in the following hours, its expression decreased particularly
in combined treatment (Figure 2(c)). Finally, p21 expression
did not vary signiﬁcantly after the treatments (Figure 2(d)).
3.3. Apoptosis and Diﬀerentiation after AS601245 and
Cloﬁbrate Treatments. Apoptosis detection is reported in
Figure 3. Both cloﬁbrate and AS601245 were unable to
induce apoptosis when added separately to CaCo-2 cells.
Conversely, the association of these two compounds induced
a signiﬁcant increase in caspase 3/7 activity, at 24 and 48
hours after the combined treatments. After 48 hours from
the combined treatment, the caspase 3/7 activity was about
4-fold higher than that detected in the control cells. These
results were conﬁrmed by using TUNEL test (data not
shown).
Diﬀerentiation of CaCo-2 cells was induced by 0.1μM
AS601245 at 48 hours after the treatment, whereas cloﬁbrate
alone did not increase the Dome number (Figure 4). Com-
bined treatment increased the Dome number after 24 hours
and caused a greater induction of diﬀerentiation compared
to single treatments, after 48 hours (an increase of about 5-
fold with respect to the control value).
3.4. Microarray Analysis of Gene Expression in CaCo-2 Cells.
To analyze whether the cell responses to the treatments with
5μMc l o ﬁ b r a t e ,0 . 1μM AS601245, or with both substances
were a consequence of a speciﬁc gene pathway modulation,
we performed microarray analysis by using the Aﬀymetrix
GeneChip platform, 24 hours after the treatments. The
completelistofthegenesmodulatedbycloﬁbrate,AS601245,
and by the combined treatment is reported in the sup-
plementary data (See Table A in Supplementary Material
available online at doi:10.1155/2012/269751). To conﬁrm
results obtained by microarray analysis, real time-PCR of
4 selected genes (2 upregulated and 2 downregulated) was
performed. Results, reported in supplementary data (Table
B), indicated that the up or down fold changes obtained
by microarray analysis were similar to those obtained in
real-time PCR. Some discrepancies were found only for
FGFR2 and CCNG that did not change in cloﬁbrate treated
cells, if evaluated by microarray analysis, whereas they were
decreased by about −1.5-fold, if analysed by real-time PCR.
The supplementary data (Table C) also indicates the genes
aﬀected by cloﬁbrate, by AS601245, and by the combined
treatment with cloﬁbrate and AS601245, arranged with
respect to the relative biological functions and listed on the
basis of the P value. The genes mainly aﬀected by cloﬁbrate,
which modulated a limited group of genes, belonged to
the “cancer,” “cellular development,” and “gene expression”
groups. AS601245 modulated genes belonging to “cancer,”
“cell cycle,” “genetic disorders,” and “cell death” groups. The
combined treatments aﬀected mainly genes belonging to
“cancer” and “genetic disorder” functions.
The Venn diagram (Figure 5) shows that cloﬁbrate mod-
ulated 182 genes, AS601245 modulated 2855 genes, and
the combined treatments modulated 848 genes. Among the
genes aﬀected by cloﬁbrate alone or AS601245 alone, 161
were common in both of the two groups. The combined
treatment aﬀected 108 genes which were present in both
the cloﬁbrate and AS601245 groups and 260 genes which
were not aﬀected by either cloﬁbrate or AS601245 alone.
Among these 260 genes, 65 only were downregulated by the
combined treatment, whereas 195 genes were upregulated.
The top ten genes changed the most by the cloﬁbrate
treatment, with respect to 1% DMSO treated cells, are
reported in Table 1. Cloﬁbrate treatment (Table 1(a)) mainly
increased the expression of the GANAB gene (3.8-fold
change) which encodes glucosidase alpha, the ATF6B gene
which encoded a transcription factor belonging the unfolded
protein response (UPR) pathway during ER stress [19, 20],
and some genes, belonging to “cancer” function (DLST,
IL6ST, MEX3d). Among genes downregulated by cloﬁbrate,
the major part belonged mainly to functional groups:
“cancer”(STIP1,HNRNPA1,VIL1,andCDH1)and“cellular
assembly and organization” (CLASP1 and MACF1).
The genes modulated by the treatments with AS601245
are indicated in Table 1(b). In this case, the gene most
upregulated was CYP1A1 (5.3 fold change). The other
genes upregulated belonged mainly to the “cancer” and cell
death functions (NFAT5, BMO2K, DLST, IL6ST, FAM76B,
and MGA). The downregulated genes belonged mainly to
the “cancer” biofunction (RPS27A, HNRNPA1, STIP1, and
TFDP1).
The top ten genes aﬀected the most by the combined
treatment with cloﬁbrate and AS601245 are reported in
Table 1(c). Among the genes upregulated by the combined
treatment, 6 were upregulated by treatments with the single
substances also. CYP1A1 was increased by 7.5-fold, whereas
AS601245 alone induced its expression by 5.3-fold. IL6ST
was induced by cloﬁbrate (2.0 fold), by AS601245 (2.5-fold
change), and, more intensively, by the combined treatmentPPAR Research 5
Cloﬁbrate
0
20
60
100
140
180
0 2 44 87 29 6
R
L
U
 
(
C
P
S
)
Control
1 μM
5 μM
25 μM
50 μM
∗∗
∗∗
∗
∗
Time (hours)
(a)
0
20
60
100
140
180
R
L
U
 
(
C
P
S
)
0 2 44 87 29 6
Time (hours)
AS601245
Control
0.1 μM
1 μM
5 μM
10 μM
∗∗
∗∗
∗∗
∗∗
∗
∗
(b)
0
20
60
100
140
180
R
L
U
 
(
C
P
S
)
0 2 44 87 29 6
Time (hours)
Control
Cloﬁbrate + AS601245
Cloﬁ 5 μM
AS 0.1 μM
Cloﬁ + AS
∗∗
∗∗
∗
∗
(c)
Figure 1: Caco-2 cell proliferation. (a) Growth of Caco-2 cells treated with cloﬁbrate at the indicated concentrations (from 1 to 50μM) and
at diﬀerent times; (b) growth of Caco-2 cells treated with AS601245 at the indicated concentrations (from 0,1 to 10μM) and at diﬀerent
times; (c) growth of Caco-2 cells treated with 5μM cloﬁbrate, 0,1μM AS601245, and the association of these two compounds (Cloﬁ +
AS601245). Cell proliferation was detected by measuring the luminescence released by the metabolically active cells. The values expressed in
RLU (relative light units) are the means ± SD of three separate experiments. Variance analysis: ∗P<0.05, ∗∗P<0.01 versus control.
(6.5-fold change). AP3D1 was increased (3.6-fold change) in
AS601245treatedcellsandwithanevengreaterincrease(5.0-
fold change) in cells treated with both compounds.
NFAT5 and GANAB genes remained almost unchanged
in combined treatment. Finally, SMRCC1 gene expression
was increased in AS601245-treated cells by a 2.0-fold change
(Table B) and by a 3.1-fold change in cells treated with
both substances. The resting genes (WASF2, VAPB, THRA,
and BDP1) were not aﬀected in cells treated with a single
compound, whereas they were highly increased in cells
treated with both substances. Among the downregulated
genes, four genes which were unaﬀected by single treatments
(TRUB1, NXT2, FGB, and ACTC1) reached the top ten
positions in the combined treatment.
Other genes downregulated with the combined treat-
ment were downregulated also, to a lesser extent, in clo-
ﬁbrate- and AS601245-treated cells (MALAT1, LARP5, and
TFRC) or in only AS601245-treated cells (SLC39A14).
Finally, two genes were downregulated by a single treatment
with AS601245 more than by the combined treatment
(HNRNPA1 and RPS27A).
We postulated that the inhibition of JNK could increase
the aﬃnity of activated PPARα for the PPRE sequences. For
this reason, we investigated, among the genes activated by
cloﬁbrate, by AS601245, and by the combined treatment,
the genes having PPRE sequences by using the genomewide
library of high-conﬁdence predicted PPAR target genes
as published by Lemay and collaborators [21]( Table 2).
It is noteworthy that, among the genes upregulated by
the cloﬁbrate 24 hours after the treatment, none had the
PPRE putative sequence in the promoter, indicating that
the cloﬁbrate, at this concentration, was not able to induce
PPARα binding to PPRE containing genes. After treatment
withAS601245andcloﬁbrate,thenumberofactivatedgenes,6 PPAR Research
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Figure 2: Proliferation-related protein expressions. (a) Determination of 0.1μM AS601245 eﬀect in reducing P-Jun expression; (b) time
course of PCNA expression in CaCo-2 cells treated with 5μM cloﬁbrate, 0.1μM AS601245, and the association of these two compounds
(Cloﬁ + AS601245); (c) time course of cyclin D1 expression in CaCo-2 cells treated with 5μM cloﬁbrate, 0.1μM AS601245, and the
association of these two compounds (Cloﬁ + AS601245); (d) time course of p21 expression in CaCo-2 cells treated with 5μM cloﬁbrate,
0.1μM AS601245, and the association of these two compounds (Cloﬁ + AS601245). Graphics represent the relative quantiﬁcation of protein
productsperformedbydensitometricscanning.Datawerenormalizedbyusingthe β-actinsignal,expressedasarbitrarydensitometricunits,
and are the mean ± SD of three separate experiments from three diﬀerent preparations for each condition. Variance analysis: ∗P<0.05,
∗∗P<0.01 versus control.
containing PPRE sequences, greatly increased (28 genes were
upregulated).
3.4.1. Eﬀect of Cloﬁbrate and AS601245 Treatments on PPARα
Binding to PPRE and Med1 Expression. Since microarray
analysis indicated that cloﬁbrate alone did not induce
expression of genes containing PPRE sequences, whereas the
treatment with AS601245 and cloﬁbrate does, we examined,
through Elisa assay, the binding of nuclear protein extracts
from control cells and cells treated with cloﬁbrate alone,
AS601245 alone, and combined treatment with cloﬁbrate
andAS601245,toPPREsequences.Figure 6(a),indicatesthat
5μM cloﬁbrate and 0.1μM AS601245 alone did not increase
the PPRE binding, whereas the PPRE binding activity was
increased in cells treated with 50μM cloﬁbrate and, more
intensively, in cells treated with 5 μM cloﬁbrate and 0.1μM
AS601245. This increase in binding activity is not linked
to the variation of PPARα phosphorylation in serine 21,PPAR Research 7
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Figure 3: Induction of apoptosis. Induction of apoptosis in CaCo-
2 cells treated with 5μM cloﬁbrate, 0.1μM AS601245, and the
association of these two compounds (Cloﬁ + AS601245). Apoptosis
was evaluated at 0, 24, and 48 hours after the treatments, by
measuring caspase 3/7 activity. 20 mM butyrate was used as a
positive control. Results normalized to the respective control value
for each experimental time is the mean ± SD of three separate
experiments from three diﬀerent preparations for each condition.
Variance analysis: ∗∗P<0.01 versus control.
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Figure 4: Induction of diﬀerentiation. Diﬀerentiation of CaCo-
2 cells treated with 5μM cloﬁbrate, 0.1μM AS601245, and the
association of these two compounds (Cloﬁ + AS601245). Cell
diﬀerentiation was evaluated at 24 and 48 hours after the start
of treatments, by measuring dome formation. 2mM butyrate was
used as a positive control. Results, expressed as number of domes
per cm2, are the mean ± SD of three separate experiments from
three diﬀerent preparations for each condition. Variance analysis:
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treated cells; #P<0.05 versus AS601245-treated cells. The picture
represents a microscopic image of domes.
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Figure 5: Microarray analysis of gene expression. Venn diagram
derived from microarray analysis of gene expression in CaCo-2 cells
treated with 5 μM cloﬁbrate, 0.1 μM AS601245, and the association
of these two compounds (Cloﬁ + AS601245) at 24 hours. The
diagram shows the number of genes modulated by the treatments.
as demonstrated by the western blot analysis with an anti-
phospho-PPAR alpha antibody (data not shown). However,
microarray analysis revealed that the PPAR alpha activator,
MED1, was increased in combined treated cells, only. To
verify if this increase corresponded to an increase in MED1
protein, we analyzed, by Western Blot, the expression of
MED1.ResultsconﬁrmedthatMED1proteinwasdoubledin
cells treated with both compounds (Figure 6(b)); moreover,
its concentration was increased in cells treated with 50μM
cloﬁbrate also. To assess whether the increase of MED1
expression was maintained in the following days in cells
exposedtocombinedtreatment,weperformedatime-course
analysis of MED1 expression. The results conﬁrmed that the
increase of MED1 expression was evident until 72 hours
after combined treatment (Figure 6(c)). Among the genes,
bearing PPRE sequences in their promoter and activated 24
hours after combined treatment, cyclin D1 has been found.
We demonstrated that cyclin D1 expression was increased
24 hours after treatment with 50μMc l o ﬁ b r a t ea n d5 μM
cloﬁbrate plus 0.1μM AS601245. These variations of cyclin
D1 expression at 24 hours were similar to those observed for
MED1 expression. (Figure 6(d)).
3.5. Analysis of JAK/STAT Signalling. The most important
gene, modulated by combined treatment, was IL6ST (also
called gp130).
This protein is the receptor for IL-6 cytokine. The bind-
ing induces the dimerization of gp130 chains resulting
in activation of Janus kinases (JAKs). JAKs phosphorylate
gp130, leading to the activation and phosphorylation of the
STAT1 and STAT3 transcription factors [22, 23]. Although
both transcription factors can be involved in gp130 down-
stream signalling, it has been demonstrated that STAT38 PPAR Research
Table 1: Top ten genesb.
(a) Cloﬁbrate
Gene ID Gene name Fold change
GANAB∗ Glucosidase, alpha; neutral AB +3.8
ATF6B Activating transcription factor 6 beta +2.8
SETD5 SET domain containing 5 +2.6
NFAT5 Nuclear factor of activated T cells 5, tonicity-responsive +2.5
DLST Dihydrolipoamide S-succinyltransferase (E2 component of 2-oxoglutarate complex) +2.3
IL6ST Interleukin 6 signal transducer (gp130, oncostatin M receptor) +2.1
HNRNPA0 Heterogeneous nuclear ribonucleoprotein A0 +2.0
MEX3D Mex-3 homolog D (C. elegans)+ 1 . 6
CTSZ Cathepsin Z +1.5
STIP 1 Stress-induced phosphoprotein 1 −3.1
CLASP 1 Cytoplasmic linker-associated protein 1 −3.1
MACF 1 Microtubule-actin cross-linking factor 1 −2.9
COPA Coatomer protein complex, subunit alpha −2.7
HNRNPA1 Heterogeneous nuclear ribonucleoprotein A1 −2.6
SPSB2 SplA/ryanodine receptor domain and SOCS box containing 2 −2.3
TSR1 TSR1, 20S rRNA accumulation, homolog (S. cerevisiae) −2.3
VIL1∗ Villin 1 −2.3
CDH1 Cadherin 1, type 1, E-cadherin (epithelial) −2.2
CRTAP Cartilage-associated protein −2.2
(b) AS601245
Gene ID Gene name Fold change
CYP1A1 Cytochrome P450, family 1, subfamily A, polypeptide 1 +5.3
AP3D1 Adaptor-related protein complex 3, delta 1 subunit +3.6
NFAT5 Nuclear factor of activated T cells 5, tonicity-responsive +3.1
BMP2K Bone morphogenetic protein 2 inducible kinase +2.9
DLST Dihydrolipoamide S-succinyltransferase (E2 component of 2-oxoglutarate complex) +2.8
IL6ST Interleukin 6 signal transducer (gp130, oncostatin M receptor) +2.8
FAM76B Family with sequence similarity 76, member B +2.4
MGA MAX gene associated +2.4
THRAP3 Thyroid hormone receptor-associated protein 3 +2.4
GANAB Glucosidase, alpha; neutral AB +2.3
RPS27A Ribosomal protein S27a −4.2
HNRNPA1 Heterogeneous nuclear ribonucleoprotein A1 −4.1
WDR33 WD repeat domain 33 −3.9
EPN1 Epsin 1 −3.7
KLC2 Kinesin light chain 2 −3.6
STIP1 Stress-induced phosphoprotein 1 −3.6
SEPT9 Septin 9 −3.4
TFDP1 Transcription factor Dp-1 −3.1
LAD1 Ladinin 1 −3.1
CABIN 1 Calcineurin-binding protein 1 −3.1
(c) Cloﬁbrate + AS601245
Gene ID Gene name Fold change
CYP1A1 Cytochrome P450, family 1, subfamily A, polypeptide 1 +7.5
IL6ST Interleukin 6 signal transducer (gp130, oncostatin M receptor) +6.4
AP3D1 Adaptor-related protein complex 3, delta 1 subunit +5.1
WASF2 WAS protein family, member 2 +4.1PPAR Research 9
(c) Continued.
Gene ID Gene name Fold change
VAPB VAMP- (vesicle-associated membrane-protein-)associated protein B and C +3.9
NFAT5∗ Nuclear factor of activated T cells 5, tonicity-responsive +3.8
THRA Thyroid hormone receptor, alpha (erythroblastic leukemia viral (v-erb-a) oncogene homolog, avian) +3.6
GANAB∗ Glucosidase, alpha; neutral AB +3.6
BDP1 B double prime 1, subunit of RNA polymerase III transcription initiation factor IIIB +3.4
SMARCC1 SWI/SNF related, matrix associated, actin-dependent regulator of chromatin, subfamily c, member 1 +3.2
TRUB1 TruB pseudouridine (psi) synthase homolog 1 (E. coli) −4.4
HNRNPA1 Heterogeneous nuclear ribonucleoprotein A1 −3.9
SLC39A14 Solute carrier family 39 (zinc transporter), member 14 −3.6
NXT2 Nuclear transport factor-2-like export factor 2 −3.4
MALAT1 Metastasis-associated lung adenocarcinoma transcript 1 (nonprotein coding) −3.2
LARP5 La ribonucleoprotein domain family, member 5 −3.0
FGB Fibrinogen beta chain −2.8
ACTC1 Actin, alpha, cardiac muscle 1 −2.8
TFRC Transferrin receptor (p90, CD71) −2.8
RPS27A Ribosomal protein S27a −2.7
bThe top ten genes upregulated and downregulated the most by 5μMC l o ﬁ b r a t e( Table 1(a)), 0.1μM AS601245 (Table 1(b)), and combined treatment
(Table 1(c)) with respect to DMSO-treated Caco-2 cells at 24h.
is necessary for the growth of colorectal cancer in mice
[24, 25]. For these reasons, we analysed in colon cancer
cells the expression of STAT3 protein and the phosphory-
lation of STAT3 after cloﬁbrate and AS601245 treatments
(Figures 7(a), 7(b), 7(c) and 7(d)). STAT 3 expression did
not vary after the treatments, and the amount of serine-
phosphorylated STAT3 did not vary either. Interestingly,
the amount of tyrosine-phosphorylated STAT3 is strongly
decreased after treatments with the highest concentration of
AS601245 and in particular after combined treatment, which
induced a synergistic decrease of phosphorylation.
3.6. Eﬀects of AS601245 and Cloﬁbrate in HepG2 Cells. Since
ﬁbrates and other drugs are principally metabolized in
liver, we tested the toxic eﬀect of 5μMc l o ﬁ b r a t e ,0 . 1 μM
AS601245, and the association of the two substances in a
liver cell line: the HepG2 cells, which has been demonstrated
to be responsive to hepatotoxic compounds [26]. Acute
toxicity was evaluated with the MTT test, performed 2 hours
after the chemical additions. The amount of viable cells was
determined by using the trypan blue dye exclusion test also.
Results conﬁrmed that 5μMc l o ﬁ b r a t e ,0 . 1 μM AS601245,
and the combined treatment with the two substances did not
cause acute toxicity in HepG2 cells (data not shown). In this
cell line, the eﬀect of cloﬁbrate, AS601245, and combined
treatment in inhibiting cell proliferation was been evalu-
ated (Figure 8(a)). All treatments reduced cell proliferation
starting from 48 hours after the beginning of experiments,
and the inhibitory eﬀect reached the maximum at 72 hours.
No signiﬁcant diﬀerences were found between the three
diﬀerent treatments. Since the reduction of proliferation can
be dependent on the modulation of speciﬁc gene expression,
we tested PCNA, cyclin D1, and p21 proliferation-related
protein expression, 24 hours after the treatments. PCNA and
cyclin D1 expression did not change after the treatments
(Figures 8(b) and 8(d)). On the contrary, p21 expression,
which did not change after the treatments in CaCo-2 cells,
was upregulated by cloﬁbrate, AS601245, and combined
treatment in HepG2 cells (Figure 8(c)).
4. Discussion
Results obtained demonstrated that the combined treatment
with cloﬁbrate and AS601245 inhibits proliferation and
downregulated the expression of two proliferation-related
proteins, PCNA and cyclin D1, 72 hours after the treatment
ofCaCO-2humancoloncells.CaspaseactivitiesandTUNEL
test demonstrated that apoptosis increased signiﬁcantly only
in cells treated with both compounds, whereas apoptosis
was not induced by such compounds, added separately. The
proapoptotic action of PPAR ligands has been reported in
many in vitro studies performed in some cancer cell lines
[27, 28]. However, at the concentration used in this study,
cloﬁbrate alone did not induce a signiﬁcant increase of
caspase activity in CaCo-2 cells. AS601245 was ineﬀective
too, although it modulated the expression of about 511 genes
belonging to the “cell death” group. On the other hand,
the JNK inhibition can elicit cellular responses, which range
from apoptosis induction to increased survival, depending
on the stimuli and the cell type [29]. Since the combined
treatment only was able to induce apoptosis, we paid
particular attention to genes, involved in the apoptotic
pathway, which were unaﬀected or slightly modulated after
the treatment with a single compound and highly modulated
by the combined treatment. Among the top ten genes
highly modulated by the combined treatment, the THRA
gene, which codiﬁes for the thyroid hormone receptor, has
been shown to be related to the apoptosis induction of10 PPAR Research
Table 2: Upregulated genes containing PPRE sequencesb.
Gene ID Gene name Fold change
Cloﬁbrate None
AS601245 CYP1A1 Cytochrome P450, family 1, subfamily A, polypeptide 1 5.3
ITGB Integrin, beta 1 (ﬁbronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) 2.9
Cloﬁbrate
+ 601245
AMFR Autocrine motility factor receptor 2.3
ANKRD12 Ankyrin repeat domain 11 2.2
CASP2 Caspase 2, apoptosis-related cysteine peptidase 2.7
CBX5 Chromobox homolog 5 (HP1 alpha homolog, Drosophila)1 . 4
CCND1 Cyclin D1 1.9
CYP1A1 Cytochrome P450, family 1, subfamily A, polypeptide 1 7.5
DDX17 DEAD (Asp-Glu-Ala-Asp) box polypeptide 17
DST Dystonin 1.8
DUSP6 Dual speciﬁcity phosphatase 6 2.2
EHBP1 EH domain-binding protein 1 2.4
EWSR1 Ewing sarcoma breakpoint region 1 1.8
FOSL1 FOS-like antigen 1 1.7
LMCD LIM and cysteine-rich domains 1 1.8
MARCKS MARCKS-like 1 2.5
MCAM Melanoma cell adhesion molecule 1.6
MLL3 Myeloid/lymphoid or mixed-lineage leukemia 3 2.7
NR2F2 Nuclear receptor subfamily 2, group F, member 2 2.4
PCYOX1 Prenylcysteine oxidase 1 1.3
RBM8A RNA-binding motif protein 8A 2.5
SPEN Spen homolog, transcriptional regulator (Drosophila) 2.2
TBL1XR1 Transducin (beta)-like 1 X-linked receptor 1 2.5
TTC3 Tetratricopeptide repeat domain 32 1.8
USP47 Ubiquitin speciﬁc peptidase 47 1.7
ZNF281 Zinc ﬁnger protein 281 1.5
ZNF294 Ring ﬁnger protein 160 1.9
bThe genes harbouring PPRE sequences among the upregulated genes by treatment with 5μMc l o ﬁ b r a t e ,0 . 1μM AS601245, and combined treatment versus
DMSO-treated Caco-2 cells at 24h.
hematopoietic progenitor cells [30]. Several other genes,
up- or downregulated by the combined treatment only,
were involved in apoptosis induction. For example, CASP2
(caspase 2, +2.8-fold change) and KLF6 (Kruppel like factor
6, +1.5 fold change) [31, 32] were upregulated, whereas
ARHGEF7 (Rho guanine nucleotide exchange factor-GEF7)
[33] and RAB23 (member Ras oncogene family) were down
regulated by a 1.9- and 2.2-fold change, respectively (Table
A).
However, the most important change in gene expression,
after combined treatment regards the IL6ST gene, which
was induced about 6 fold, 24 hours after the treatment, as
demonstrated by aﬀymetric analysis and conﬁrmed by RT-
PCR. IL6ST (or gp130) is a universal signal transducing
receptor for all IL-6 family cytokines [34] .T h er o l ep l a y e d
by IL-6 signalling in mediating tumour growth is equivo-
cal [35], in certain tumour cells, it inhibits proliferation,
whereas, in “in vivo” models, it stimulates cell growth.
Moreover, the signiﬁcance of an increase of gp130 expression
also is controversial: on one hand, it may indicate an
increase in the response to the IL-6 family cytokine stimuli,
on the other hand, the soluble form signalling receptor
subunit gp130, which is generated by diﬀerential splicing,
is the natural inhibitor of IL-6 trans-signalling responses
[35]. We analyzed the downstream signalling of gp130,
through the analysis of STAT3 phosphorylation. STAT3 is
constitutively active in most tumor cells but not in normal
cells. Phosphorylation of STAT3 at tyrosine 705 leads to
its dimerization, nuclear translocation, DNA binding, and
gene transcription. The phosphorylation of STAT3 at serine
727 may regulate its activity negatively or positively [36].
AS601245 and, at higher level, the combined treatment
reduced STAT3 phosphorylation at tyrosine 705, indicating
a strong inhibition of STA3-induced gene transcription.
STAT3regulatestheexpressionofgenesthatmediatesurvival
and proliferation and can be involved in apoptosis inductionPPAR Research 11
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Figure 6: PPRE binding activity and Western Blot analysis of Med1 and cyclin D1. (a) PPRE binding activity of PPARα. Results represent
the absorbance, detected at 450nm, subtracted from the control value, and are the mean ± SD of three separate experiments from three
diﬀerent preparations for each condition; (b) Western Blot analysis of Med1 protein detected in CaCo-2 cells treated with 5μMa n d5 0μM
cloﬁbrate (Cloﬁ), 0.1μM AS1245, and 5μM cloﬁbrate plus 0.1μM AS601245 (Cloﬁ + AS601245), collected at 24 hours after the treatment;
(c) Western Blot analysis of Med1 protein detected in CaCo-2 cells treated with 5μM cloﬁbrate, 0.1μM AS1245, and 5μM cloﬁbrate plus
0.1μM AS601245 (Cloﬁ + AS), collected at 24, 48, and 72 hours after the treatment; (d) Western Blot analysis of cyclin D1 detected in CaCo-
2 cells treated with 5μMa n d5 0μM cloﬁbrate (Cloﬁ), 0.1μM AS1245, and 5μM Cloﬁbrate plus 0.1μM AS601245 (Cloﬁ + AS601245),
collected at 24 hours after the treatment. Graphics represent the relative quantiﬁcation of protein products performed by densitometric
scanning. Data were normalized by using the β-actin signal, expressed as arbitrary densitometric units, and are the mean ± SD of three
separate experiments from three diﬀerent preparations for each condition. Variance analysis: ∗P<0.05, ∗∗P<0.01 versus control.
and in reduction of cell proliferation caused by combined
treatment. Interestingly, AS601245 alone reduced in a dose-
dependent way STAT3 phosphorylation. This result is in
agreement with the work by Kim et al. [37] demonstrating
that a JNK inhibitor negatively correlated with the viability
of cancer cells and reduced STAT3 activity.
As far as it regards diﬀerentiation induction, cloﬁbrate
alone did not increase diﬀerentiation of CaCo-2 cells.
AS601245 is more eﬀective than cloﬁbrate in inducing
diﬀerentiation, and it shows a synergistic eﬀect when added
together with cloﬁbrate. As well as for the apoptosis induc-
tion, the action of JNK in diﬀerentiation is controversial.
Ding and collaborators demonstrated that diﬀerentiation is
associated with increased JNK activity and c-Jun phosphory-
lation [38]. In agreement with these ﬁndings, inhibition of
JNK has been shown to attenuate intestinal cell diﬀerentia-
tion [39]. On the contrary, other authors demonstrated that
the MAP kinase pathway inhibitor U0126, in combination12 PPAR Research
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Figure7:AnalysisofJAK/STATsignalling.WesternBlotanalysisofSTAT3(a),P-STAT3(Ser727)(b),andP-STAT3(Tyr705)(c)proteinslevels
analyzed in CaCo-2 cells treated with cloﬁbrate (Cloﬁ) alone, AS601245 alone at the indicated concentrations, and combined treatment with
5μMcloﬁbrateand0,1μMAS601245(Cloﬁ+AS)andcollectedat24hoursafterthetreatment.Graphicsrepresenttherelativequantiﬁcation
of protein products performed by densitometric scanning. Data were normalized by using the β-actin signal and expressed as arbitrary
densitometric units. (d) Graphics represent the normalization of the protein level of P-STAT3 (Tyr705) by using STAT3 signal. Results are
the mean ± SD of three separate experiments from three diﬀerent preparations for each condition. Variance analysis: ∗P<0.05, ∗∗P<0.01
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Figure 8: Eﬀect of cloﬁbrate and AS601245 in HepG-2 human liver cells. (a) Growth of HepG-2 cells treated with 5μM cloﬁbrate, 0,1 μM
AS601245, and the association of these two compounds (Cloﬁ + AS601245); (b) Western Blot analysis of PCNA detected in CaCo-2 cells
treated with 5μM cloﬁbrate, 0.1 μM AS1245, and 5μM cloﬁbrate plus 0.1μM AS601245 (Cloﬁ + AS601245), collected at 24 hours after the
treatment; (c) Western Blot analysis of p21, detected in CaCo-2 cells treated with 5μM cloﬁbrate, 0.1μM AS1245, and 5μM cloﬁbrate plus
0.1μMAS601245(Cloﬁ+AS601245),collectedat24hoursafterthetreatment;(d)WesternBlotanalysisofcyclinD1detectedinCaCo-2cells
treated with 5μM cloﬁbrate, 0.1μM AS1245, and 5μM cloﬁbrate plus 0.1μM AS601245 (Cloﬁ + AS601245), collected at 24 hours after the
treatment. Graphics represent the relative quantiﬁcation of protein products performed by densitometric scanning. Data were normalized
by using the β-actin signal, expressed as arbitrary densitometric units, and are the mean ± SD of three separate experiments from three
diﬀerent preparations for each condition. Variance analysis: ∗P<0.05, ∗∗P<0.01 versus control.
with butyrate, promotes diﬀerentiation in some colon cancer
celllines[40].OurresultsdemonstratedthatAS601245,at24
hours, did not increase the number of Domes, whereas, after
48 hours, diﬀerentiation induction was evident. Moreover,
the addition of AS601245 to cloﬁbrate increased the diﬀer-
entiation of CaCo-2 cells both at 24 and 48 hours.
By analysing the expression proﬁle of the genes involved
in this pathway, we found some genes aﬀected by AS601245,
which were further modulated by the association of these
two compounds (Table A). A role, in the diﬀerentiation-
process, may be played by the MGA gene, activated by 2.361-
fold in AS601245-treated cells and by 3.089-fold in cells
treated with AS601245 and cloﬁbrate. This gene codiﬁes a
member of MAD family proteins belonging to the Max/Mad
network which is involved in the control of various aspects
ofcellbehaviour,includingproliferation,diﬀerentiation,and
apoptosis [41].
Cloﬁbrate alone, at the concentration of 5μM, did not
activate genes containing PPRE sequences, probably because
of its low concentration. However, whenadded together with
AS601245, 28 genes containing putative PPRE sequences
were upregulated. This datum is in agreement with the
hypothesis of an increase of PPAR transcriptional activ-
ity after JNK inhibition [42] and is further sustained14 PPAR Research
by the results obtained in PPRE binding activity, which
demonstrated a strong increase in DNA binding of cells
treated with both AS601245 and cloﬁbrate. The gene
expression proﬁle revealed that the expression of the
PPARα activator MED1 was increased by 1.8-fold in cells
treated with both compounds only. MED1 (also referred as
PBP/TRAP220/DRIP205)wasshownasacriticalcomponent
of the TRAP/DRIP/ARC/Mediator complex [43]w h i c h
facilitates interaction of ligand-activated PPAR with RNA
polymerase and the general basal transcription machinery
to enhance the transcription of a speciﬁc set of genes [44–
46]. Western Blot analysis conﬁrmed the increase of MED1
protein in cells treated with 5μM cloﬁbrate plus 0.1μM
AS691245. This increase remained elevated in the cells
treated with both compounds until 72 hours after the treat-
ment. Moreover, an increase of MED1 expression occurred
evenin50μMcloﬁbrate-treatedcells.Theseresultsparalleled
with the increase of PPRE binding activity and may suggest
thatMED1expressionwasinvolvedinincreasingthenumber
of genes, containing PPRE sequences, activated by combined
treatment. According to this hypothesis, we demonstrated
that the expression of cyclin D1 protein, codiﬁed by a
gene containing PPRE sequences that was upregulated after
combined treatment, was increased, not only after combined
treatment, but also after treatment with 50μM cloﬁbrate.
The experiments performed in HepG2 cells showed
that the single and combined treatment did not induce
hepatotoxicity in human liver cells. Moreover, the analysis of
the eﬀect of these compounds on HepG2 cells proliferation
indicated that there was no synergistic eﬀect between
cloﬁbrate and AS601245. In this cell line, the pattern of
proliferation-related protein expression was diﬀerent from
that detected in CaCO-2 cells. Indeed, in HepG-2 cells, the
p21 expression was increased in cloﬁbrate, AS601245 and
cloﬁbrate plus AS601245, treated cells. This result may be
related to the fact that HepG2 cells have a wild-type p53 gene
[47], whereas, in CaCo-2 cells, p53 is not expressed [48].
5. Conclusions
Taken together, our data demonstrate the eﬀectiveness of
combined treatments with PPARα agonists and a JNK
inhibitor in inducing apoptosis, diﬀerentiation, and PPRE
binding activity in colon cancer cells and support the data
suggesting a positive interaction between PPARα ligands and
anti-inﬂammatory agents in humans [49, 50]. The positive
interaction originates from the modulation of several sig-
nalling pathways which were aﬀected by the association of
cloﬁbrate and AS601245.
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